Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Jun 05, 2023
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK , June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
May 18, 2023
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models IND enabling studies underway; IND filing on track for 2024 NEW YORK , May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage
Corporate Presentation

SEC Filings

Form Description Filing date View
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-23-014410.pdf
0000899243-23-014410.rtf
0000899243-23-014410.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-23-014412.pdf
0000899243-23-014412.rtf
0000899243-23-014412.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-23-014409.pdf
0000899243-23-014409.rtf
0000899243-23-014409.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-23-014415.pdf
0000899243-23-014415.rtf
0000899243-23-014415.xls

Data provided by Kaleidoscope.

Events and Presentations